|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
SEPTEMBER 6, 2004
Ready To Rebound At Angiotech Boston Scientific's (BSX ) July 2 recall of its drug-coated stents has sent shares tumbling 17%. Some analysts call it a buying opportunity. And, they say, little-known Angiotech Pharmaceuticals (ANPI ), a specialty outfit in Vancouver, may be an even better bet.  Angiotech, now trading at 17.51, licenses its stent-coating technology to Boston Scientific, and analyst Ashkan Haghighat of BMO Nesbitt Burns is upbeat about its cutting-edge technology. He initiated coverage on Aug. 12 with a 12-month price target of 23. Jayson Bedford at investment outfit Adams Harness calls the company a pioneer in drug-coated medical devices and says the current valuation doesn't account for its deep pipeline of key patents. The stock has a p-e ratio of 23, based on his 2005 earnings estimate of 86 cents. His conservative price target is 20. Another plus: Angiotech holds cash of $3 a share.Gene Marcial will be back next week. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Mara Der Hovanesian Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2004, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version
